DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION					
DISTRICT OFFICE ADDRESS AND PHONE NUMBER			DATE(S) OF INSPECTION		
555 Winderley Place, Suite 200 Maitland, FL 32751 407-475-4700			2/3-2/5/20 & 2/7/20		
			FEI NUMBER		
Industry Information: www fda.gov/oc/industry			3011103365		
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT IS ISSUED					
To: Anish Chemparathy, R.Ph., Pharmacist in Charge & Owner					
FIRM NAME STREE		STREET ADDRESS			
All the state of t		12116 Cortez Blvd.			
CITY, STATE AND ZIP CODE		DESCRIPTION OF THE SECOND WEST SECTION OF THE SECOND SECTION OF THE SECOND SECTION OF THE SECOND SECTION OF THE SECOND SE	TYPE OF ESTABLISHMENT INSPECTED		
Brooksville, FL 34613 Producer of Non-		Producer of Non-Steri	erile Drug Products		
THIS DOCUMENT LISTS OBSERVATIONS MADE BY THE FDA REPRESENTATIVE(S) DURING THE INSPECTION OF YOUR FACILITY. THEY ARE INSPECTIONAL OBSERVATIONS; AND DO NOT REPRESENT A FINAL AGENCY DETERMINATION REGARDING YOUR COMPLIANCE. IF YOU HAVE AN OBJECTION REGARDING AN OBSERVATION, OR HAVE IMPLEMENTED, OR PLAN TO IMPLEMENT CORRECTIVE ACTION IN RESPONSE TO AN OBSERVATION, YOU MAY DISCUSS THE OBJECTION OR ACTION WITH THE FDA REPRESENTATIVE(S) DURING THE INSPECTION OR SUBMIT THIS INFORMATION TO FDA AT THE ADDRESS ABOVE. IF YOU HAVE ANY QUESTIONS, PLEASE CONTACT FDA AT THE PHONE NUMBER AND ADDRESS ABOVE.  DURING AN INSPECTION OF YOUR FIRM (I) (WE) OBSERVED:					
BONALO AVINOLEGION OLI POSITI INMI (I) (ME) OBSELVES.					
Observation 1: Non-microbial contamination was observed in your production area.					
Specifically, on 2/3/20, within the firm's Non-Sterile Suite ((b) (4) Hood, (b) (4)), the vent directly over the working surface was observed visually un-clean, shedding and to contain an unknown brown residue. According to your firm's Pharmacist in Charge/Owner, the vent has not been replaced in approximately two years (all non-sterile drug products are produced within this hood).  Observation 2: Hazardous drugs were produced without providing adequate containment, segregation, and/or cleaning of work surfaces, utensils, and/or personnel to prevent cross-contamination.  Specifically, on 11/25/19, your firm produced the following non-sterile drug products: Estradiol 0.1mg/g Cream, Rx (b) (6) , Exp.: 90 Days (hazardous), Testosterone 1mg/mL Cream, Rx (b) (6) , Exp.: 90 Days (hazardous) and Naltrexone 4mg Capsules, Rx (b) (6) , Exp.:180 Days (non-hazardous) within the (b) (4) (b) (4) Hood, (b) (4) without providing adequate containment, segregation, and/or cleaning of the work surfaces.					
Add Continuation Page					
	EMDLOVEE/S) SIGNATURE	EMDLOVEE/S) NAME AND TITLE	= (Print or Type)	DATE ISSUED	
SEE REVERSE OF THIS PAGE	Jessica L. Pressley -5  Digitally signed by Jass cal. Priess or 5  D	Jessica L. Pressley, Drug Sp	18 2 8 2 1 UZ	02/07/2020	